| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
585,690,000 |
| Market
Cap: |
183.24(B) |
| Last
Volume: |
2,920,983 |
Avg
Vol: |
2,722,478 |
| 52
Week Range: |
$214.27 - $324.56 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
S&P COMPOSITE 1500 |
|
NASDAQ BIOTECHNOLOGY |
| |
NASDAQ COMPOSITE |
|
NASDAQ-100 |
| |
S&P 100 |
|
S&P 500 |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 499 |
| Guru Rank Value : 3 |
| Guru Occurances : 2 |
|
|
|
|
|
| |
|
Company Profile Amgen is a biotechnology company that focuses on discovering, developing, manufacturing and delivering human therapeutics. Co.'s principal products are Enbrel® (etanercept), Prolia® (denosumab), Otezla® (apremilast), XGEVA® (denosumab), Neulasta® (pegfilgrastim), Aranesp® (darbepoetin alfa), Repatha® (evolocumab), KYPROLIS® (carfilzomib) and Nplate® (romiplostim). Co. also markets a number of other products, including among other, MVASI® (bevacizumab-awwb), Vectibix® (panitumumab), KANJINTI® (trastuzumab-anns), EVENITY® (romosozumab-aqqg), EPOGEN® (epoetin alfa), BLINCYTO® (blinatumomab), AMGEVITA™ (adalimumab), Aimovig® (erenumab-aooe), Parsabiv® (etelcalcetide) and NEUPOGEN® (filgrastim).
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
2,117 |
14,213 |
23,771 |
45,603 |
| Total Sell Value |
$662,802 |
$3,963,214 |
$6,471,520 |
$11,852,673 |
| Total People Sold |
1 |
2 |
3 |
6 |
| Total Sell Transactions |
1 |
3 |
4 |
10 |
| End Date |
2024-02-08 |
2023-11-07 |
2023-05-09 |
2022-05-09 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Griffith Peter H. |
EVP & CFO |
• • – |
2024-05-07 |
4 |
A |
$0.00 |
$0 |
D/D |
3,196 |
35,973 |
|
- |
|
| Gordon Murdo |
EVP, Global Commercial Ops |
• • – |
2024-05-07 |
4 |
A |
$0.00 |
$0 |
D/D |
3,529 |
52,674 |
|
- |
|
| Busch Matthew C. |
VP, Finance & CAO |
• • – |
2024-05-07 |
4 |
A |
$0.00 |
$0 |
D/D |
333 |
4,932 |
|
- |
|
| Bradner James E. |
EVP, R&D, & Chief Sci. Officer |
• • – |
2024-05-07 |
4 |
A |
$0.00 |
$0 |
D/D |
2,863 |
25,438 |
|
- |
|
| Reese David M |
EVP & Chief Technology Officer |
• • – |
2024-05-07 |
4 |
A |
$0.00 |
$0 |
D/D |
3,196 |
61,889 |
|
- |
|
| Grygiel Nancy A. |
SVP & CCO |
• • – |
2024-05-07 |
4 |
A |
$0.00 |
$0 |
D/D |
499 |
10,300 |
|
- |
|
| Santos Esteban |
EVP, Operations |
• • – |
2024-05-07 |
4 |
A |
$300.30 |
$899,999 |
D/D |
2,997 |
71,304 |
|
- |
|
| Khosla Rachna |
SVP, Business Development |
• • – |
2024-05-07 |
4 |
A |
$0.00 |
$0 |
D/D |
532 |
8,559 |
|
- |
|
| Miller Derek |
SVP, Human Resources |
• • – |
2024-05-07 |
4 |
A |
$0.00 |
$0 |
D/D |
865 |
8,983 |
|
- |
|
| Bradway Robert A |
Chairman, CEO and President |
• • – |
2024-05-07 |
4 |
A |
$0.00 |
$0 |
D/D |
11,988 |
669,269 |
|
- |
|
| Graham Jonathan P |
EVP & Gen. Counsel & Secy. |
• • – |
2024-05-07 |
4 |
A |
$0.00 |
$0 |
D/D |
2,863 |
35,186 |
|
- |
|
| Ishrak Omar |
Director |
• • – |
2024-05-07 |
4 |
A |
$0.00 |
$0 |
D/D |
117 |
3,977 |
|
- |
|
| Holley Charles M |
Director |
• • – |
2024-05-07 |
4 |
A |
$0.00 |
$0 |
D/D |
142 |
8,855 |
|
- |
|
| Drake Michael V |
Director |
• • – |
2024-05-07 |
4 |
A |
$0.00 |
$0 |
D/D |
117 |
2,456 |
|
- |
|
| Santos Esteban |
EVP, Operations |
• • – |
2024-05-05 |
4 |
D |
$311.29 |
$192,066 |
D/D |
(617) |
68,307 |
|
- |
|
| Reese David M |
EVP & Chief Technology Officer |
• • – |
2024-05-05 |
4 |
D |
$311.29 |
$197,047 |
D/D |
(633) |
58,693 |
|
- |
|
| Busch Matthew C. |
VP, Finance & CAO |
• • – |
2024-05-05 |
4 |
D |
$311.29 |
$8,405 |
D/D |
(27) |
4,599 |
|
- |
|
| Griffith Peter H. |
EVP & CFO |
• • – |
2024-05-05 |
4 |
D |
$311.29 |
$201,716 |
D/D |
(648) |
32,777 |
|
- |
|
| Gordon Murdo |
EVP, Global Commercial Ops |
• • – |
2024-05-05 |
4 |
D |
$311.29 |
$207,008 |
D/D |
(665) |
49,145 |
|
- |
|
| Khosla Rachna |
SVP, Business Development |
• • – |
2024-05-05 |
4 |
D |
$311.29 |
$12,763 |
D/D |
(41) |
8,027 |
|
- |
|
| Bradway Robert A |
Chairman, CEO and President |
• • – |
2024-05-05 |
4 |
D |
$311.29 |
$691,064 |
D/D |
(2,220) |
657,281 |
|
- |
|
| Miller Derek |
SVP, Human Resources |
• • – |
2024-05-05 |
4 |
D |
$311.29 |
$24,281 |
D/D |
(78) |
8,118 |
|
- |
|
| Graham Jonathan P |
EVP & Gen. Counsel & Secy. |
• • – |
2024-05-05 |
4 |
D |
$311.29 |
$196,735 |
D/D |
(632) |
32,323 |
|
- |
|
| Grygiel Nancy A. |
SVP & CCO |
• • – |
2024-05-05 |
4 |
D |
$311.29 |
$25,526 |
D/D |
(82) |
9,801 |
|
- |
|
| Grygiel Nancy A. |
SVP & CCO |
• • – |
2024-05-03 |
4 |
S |
$313.09 |
$662,802 |
D/D |
(2,117) |
9,883 |
|
1% |
|
2195 Records found
|
|
Page 1 of 88 |
|
|
5.55 (1.81%) 
